Inclusion Criteria:  Histologically confirmed advanced cancer of any tumor type (Part 1) or NSCLC with a confirmed KRAS mutation as determined by local results (Part 2) Appropriate candidate for experimental therapy For patients in Part 2 only: Patient has radiographically measurable disease per RECIST 1.1 criteria. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. Adequate cardiac function (Left ventricular ejection fraction (LVEF) ≥50% ) Adequate organ function Must have tumor tissue specimen available (optional for patients in Part 1)  Exclusion Criteria:  History or current evidence of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues Current evidence of clinically significant corneal or retinal disorder as confirmed by ophthalmologic examination. Known untreated central nervous system (CNS) metastases or history of uncontrolled seizures. Significant gastrointestinal disorder(s) that could interfere with absorption of futibatinib/binimetinib Patients who have neuromuscular disorders that are associated with elevated creatinine kinase (CK)